An illustration · invented records
Oncology office names the tumor test
Record type: patient-portal message thread, copied from Mom’s portal. Mom typed the question with me beside her; the reply came from the practice’s oncology nurse. When: question sent September 5, 4:50 pm. Reply received September 8, 10:14 am.
Mom’s message, September 5:
At my visit on September 3 the doctor mentioned a test on the tumor that could help decide whether chemotherapy would add anything for me. I didn’t catch the name and it isn’t in my visit summary. Could you tell me what the test is called, what it is for, and whether it has been ordered? Thank you.
Reply from the oncology nurse, September 8:
Thank you for your message. I reviewed your visit note with the doctor. The test discussed is the Oncotype DX Breast Recurrence Score, a 21-gene test performed on a sample of the tumor tissue. For patients whose cancer is hormone-receptor positive and HER2 negative, it gives a score that the oncologist uses, together with the rest of your pathology, to estimate how likely the cancer is to come back and whether adding chemotherapy to anti-estrogen therapy is likely to be helpful.
It is usually ordered after surgery, on the tumor that is removed, once the final pathology including the lymph node results is available. It has not been ordered at this time. Whether it is appropriate for you will be discussed after surgery, and you are welcome to raise it at your second-opinion visit as well.
Please let us know if you have further questions.
What we learned and what to ask next:
- The office named the test, explained its purpose, and confirmed it has not been ordered.
- Whether the test would help with Mom’s care, and what a result would mean for her, remain questions for Mom and her clinicians after surgery.
- The research question in this file now has a definite subject: what the published evidence says about this test, and its limits.